Risankizumab Efficacy for Moderate-to-Severe Plaque Psoriasis over 256 Weeks in Patients with Prior Biologic Treatments

Introduction: Risankizumab, a biologic interleukin 23 inhibitor, is approved for the treatment of moderate-to-severe plaque psoriasis. Patients previously treated with a biologic may experience decreased efficacy when receiving a subsequent biologic. Here, we examined the long-term efficacy of RZB in patients with a history of prior biologic use.